Volume trends indicate cautious institutional positioning, and any FDA-related updates could act as catalysts. Our information suggests that Novavax, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.0m worth of stock. This compares to a market capitalization of US$641m. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling. CSX Stock Rally: Strong Options Flow, Analyst Price Targets Some strategists maintain a cautious nvax stock price forecast, citing broader market headwinds and biotech sector rotation. Correlation with Nasdaq Biotech Index trends remains elevated.